<p>莱斯康制药公司（NASDAQ:LXRX - 获取免费报告）在周五的午盘交易中，股价上涨了 5.8%，因该公司公布的季度收益超出预期。该公司股价最高达到 1.74 美元，最后交易价为 1.7350 美元。在午盘交易中，约有 1,928,143 股交易，较平均交易量 2,946,142 股下降了 35%。该股票此前收盘价为 1.64 美元。</p>
<p>这家生物制药公司报告的季度每股收益（EPS）为（$0.04），超出分析师共识预期的（$0.07）$0.03。该季度的收入为 549 万美元，而分析师预期为 314 万美元。莱斯康制药的净利润率为负 96.77%，股本回报率为负 52.90%。</p>
<h2>影响莱斯康制药的关键头条</h2>
<p>以下是本周影响莱斯康制药的关键新闻：</p>
<ul>
<li>积极情绪：第四季度业绩超出预期：GAAP 每股收益为-$0.04，预期为-$0.07，收入为 549 万美元，预期为 314 万美元——每股收益和收入的上行支持近期乐观情绪。莱斯康制药的 GAAP 每股收益-$0.04 超出$0.03，收入 549 万美元超出$2.35 百万。</li>
<li>积极情绪：临床和公司进展：管理层表示，关键的 sotagliflozin 里程碑仍按计划进行（T1D 的 NDA 重新提交，HCM 的 SONATA 入组），而 pilavapadin 在 FDA 的第二阶段结束会议上获得积极反馈，支持第三阶段的准备——这些降低了即将到来的催化剂的风险。该公司还报告了超过 1 亿美元的额外现金来自资本筹集和诺和诺德的里程碑，增强了资产负债表。莱斯康制药报告了 2025 年第四季度财务结果并提供临床更新。</li>
<li>积极情绪：分析师升级/目标价上调：HC Wainwright 重申买入评级，并将目标价从 4 美元上调至 6 美元，暗示从当前水平有显著上行——分析师的支持可以吸引买入兴趣。Benzinga 对 HC Wainwright 目标价上调的报道。</li>
<li>中性情绪：会议材料和电话会议记录可用：该公司发布了新闻稿、幻灯片和召开了电话会议（记录可用）——对挖掘指导、现金流和试验时间表有用，但本身并不是直接的价格驱动因素。查看新闻稿/幻灯片。</li>
<li>中性情绪：多个媒体发布了财报电话会议记录和快照（Seeking Alpha, InsiderMonkey, Yahoo, WTOP）——增加了透明度和覆盖面，但主要重申了相同的业绩和更新。InsiderMonkey 财报电话会议记录。</li>
<li>消极情绪：公司仍处于亏损状态，负的股本回报率和净利润率；共识仍预计全年每股收益亏损（当前共识约为-$0.66）。持续的临床和监管风险加上负的收益预测意味着上行依赖于成功的试验和监管结果。MarketBeat 公司简介和共识预期。</li>
</ul>
<h2>分析师设定新的目标价</h2>
<p>几位研究分析师对 LXRX 股票发表了评论。Weiss Ratings 在 1 月 22 日的研究报告中重申了对莱斯康制药股票的 “卖出（d-）” 评级。华尔街 Zen 在 11 月 15 日的报告中将莱斯康制药的股票评级从 “买入” 下调至 “持有”。最后，HC Wainwright 在周四的研究报告中将莱斯康制药的目标价从 4.00 美元上调至 6.00 美元，并给予该公司 “买入” 评级。三位研究分析师对该股票给予了买入评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，莱斯康制药目前的共识评级为 “适度买入”，平均目标价为 4.63 美元。</p>
<p><strong>获取我们关于莱斯康制药的最新研究报告</strong></p>
<h2>内部活动</h2>
<p>在相关消息中，董事 Raymond Debbane 于 2 月 23 日星期一以每股平均 1.47 美元的价格收购了 100,000 股该公司的股票，总交易额为 147,000.00 美元。收购完成后，该董事直接持有公司 1,904,186 股股票，价值约为 2,799,153.42 美元。此次交易使其持股增加了 5.54%。该交易已在 SEC 的备案中披露，可通过 SEC 网站获取。此外，董事 Invus Global Management, Llc 于 2 月 2 日星期一购买了 1,538,462 股该公司的股票，购买价格为每股 1.30 美元，总交易额为 2,000,000.60 美元。收购后，该董事持有 1,538,462 股该公司的股票，价值为 2,000,000.60 美元。这代表其持股增加了∞。该购买的披露信息可在 SEC 备案中找到。在过去一个季度，内部人士购买了价值 2,369,981 美元的 1,790,462 股公司股票。目前，内部人士持有该股票的 13.90%。</p>
<h2>机构资金流入和流出</h2>
<p>几家对冲基金和其他机构投资者最近对 LXRX 的持仓进行了调整。瑞银集团在第四季度将其在莱克森制药的股份增加了 752.1%。瑞银集团目前拥有 3,007,237 股该生物制药公司的股票，价值 3,458,000 美元，此前在上个季度又购买了 2,654,315 股。CIBC Bancorp USA Inc. 在第三季度购买了莱克森制药的新股份，价值约 3,240,000 美元。千禧管理公司在第三季度将其在莱克森制药的持股增加了 133.1%。千禧管理公司目前拥有 3,830,660 股该生物制药公司的股票，价值 5,171,000 美元，此前在上个季度又购买了 2,187,396 股。Marshall Wace LLP 在第四季度获得了莱克森制药的新职位，价值约 1,452,000 美元。最后，AQR Capital Management LLC 在第一季度获得了莱克森制药的新股份，价值 541,000 美元。目前，74.70% 的股票由机构投资者和对冲基金持有。</p>
<h2>莱克森制药价格表现</h2>
<p>该股票的市值为 6.2335 亿美元，市盈率为 -9.03，贝塔值为 0.94。该股票的 50 日简单移动平均为 1.35 美元，200 日简单移动平均为 1.33 美元。公司的流动比率为 5.64，速动比率为 5.63，债务与股本比率为 0.47。</p>
<h2>关于莱克森制药</h2>
<p>（获取免费报告）</p>
<p>莱克森制药公司是一家生物制药公司，专注于通过其专有的基因组生物学平台发现和开发新药。通过利用大规模基因敲除文库，公司识别潜在的治疗靶点，并将其推进到临床前和临床开发阶段。莱克森的做法强调将基因洞察转化为针对多种人类疾病的靶向疗法。</p>
<p>该公司的最先进产品是乙基特洛曲司特（以品牌名 XERMELO 销售），这是一种口服治疗药物，已获批准用于管理在生长抑素类似物治疗下控制不佳的类癌综合症腹泻患者。</p>
<h2>特色文章</h2>
<ul>
<li>五只我们更看好的股票，胜过莱克森制药</li>
<li>BNZI 在 Zacks 买入评级中脱颖而出。盈利势头和分析师升级一致</li>
<li>摩根大通正在押注这枚硬币</li>
<li>你的名字尚未在我们的保护名单上</li>
<li>~1.5 万亿美元的 SpaceX IPO：首次公开募股机会</li>
<li>用这四个简单步骤 “防联储” 你的银行账户</li>
</ul>
<p><em>此即时新闻提醒是通过叙述科学技术和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在莱克森制药吗？</h2>
<p>在考虑莱克森制药之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而莱克森制药并不在名单上。</p>
<p>虽然莱克森制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

纽交所高增长板生物技术指数 ETF - First Trust

动态生物技术与基因组 ETF - Invesco

医疗业 ETF - SPDR

<p>莱斯康制药（NASDAQ:LXRX）股价上涨 5.8%，因公司公布的季度财报超出预期，每股收益为-0.04 美元，优于预期的-0.07 美元，营收为 549 万美元，超过预期的 314 万美元。尽管净利润率和股本回报率为负，分析师们仍然保持乐观，HC Wainwright 将其目标价从 4 美元上调至 6 美元。内部人士的买入活动也有所增加，董事们进行了大量购买。然而，公司仍面临盈利能力挑战和临床风险</p>

<p>Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report)'s stock price shot up 5.8% during mid-day trading on Friday after the company announced better than expected quarterly earnings. The company traded as high as $1.74 and last traded at $1.7350. Approximately 1,928,143 shares traded hands during mid-day trading, a decline of 35% from the average session volume of 2,946,142 shares. The stock had previously closed at $1.64.</p>
<div class="lb-trans"><p>莱斯康制药公司（NASDAQ:LXRX - 获取免费报告）在周五的午盘交易中，股价上涨了 5.8%，因该公司公布的季度收益超出预期。该公司股价最高达到 1.74 美元，最后交易价为 1.7350 美元。在午盘交易中，约有 1,928,143 股交易，较平均交易量 2,946,142 股下降了 35%。该股票此前收盘价为 1.64 美元。</p>
</div><p>The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.07) by $0.03. The company had revenue of $5.49 million during the quarter, compared to analysts' expectations of $3.14 million. Lexicon Pharmaceuticals had a negative net margin of 96.77% and a negative return on equity of 52.90%.</p>
<div class="lb-trans"><p>这家生物制药公司报告的季度每股收益（EPS）为（$0.04），超出分析师共识预期的（$0.07）$0.03。该季度的收入为 549 万美元，而分析师预期为 314 万美元。莱斯康制药的净利润率为负 96.77%，股本回报率为负 52.90%。</p>
</div><h2>Key Headlines Impacting Lexicon Pharmaceuticals</h2>
<div class="lb-trans"><h2>影响莱斯康制药的关键头条</h2>
</div><p>Here are the key news stories impacting Lexicon Pharmaceuticals this week:</p>
<div class="lb-trans"><p>以下是本周影响莱斯康制药的关键新闻：</p>
</div><ul>
<li>Positive Sentiment: Q4 results beat expectations: GAAP EPS of -$0.04 vs. consensus -$0.07 and revenue of $5.49M vs. $3.14M — the upside to both EPS and revenue supports near-term optimism. Lexicon Pharmaceuticals GAAP EPS of -$0.04 beats by $0.03, revenue of $5.49M beats by $2.35M</li>
<li>Positive Sentiment: Clinical and corporate progress: management said pivotal sotagliflozin milestones remain on schedule (NDA resubmission in T1D, SONATA enrollment for HCM) and pilavapadin received a positive End-of-Phase 2 FDA meeting supporting Phase 3 readiness — these de-risk upcoming catalysts. The company also reported &gt;$100M of additional cash from a capital raise and a Novo Nordisk milestone, strengthening the balance sheet. Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates</li>
<li>Positive Sentiment: Analyst upgrade / price-target lift: HC Wainwright reiterated a Buy and raised its PT from $4 to $6, implying substantial upside from current levels — analyst support can attract buying interest. Benzinga coverage of HC Wainwright PT raise</li>
<li>Neutral Sentiment: Conference materials and call transcripts available: the company filed a press release, slide deck and held a conference call (transcripts available) — useful for digging into guidance, cash runway and trial timelines but not a direct price driver by itself. View Press Release / Slide Deck</li>
<li>Neutral Sentiment: Multiple outlets published earnings call transcripts and snapshots (Seeking Alpha, InsiderMonkey, Yahoo, WTOP) — increases transparency and coverage but mainly reiterates the same beats and updates. InsiderMonkey earnings call transcript</li>
<li>Negative Sentiment: Company remains unprofitable with negative ROE and net margin; consensus still expects a full-year EPS loss (current consensus ~ -$0.66). Continued clinical and regulatory risk plus negative earnings projections mean upside depends on successful trial and regulatory outcomes. MarketBeat company profile and consensus estimates</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：第四季度业绩超出预期：GAAP 每股收益为-$0.04，预期为-$0.07，收入为 549 万美元，预期为 314 万美元——每股收益和收入的上行支持近期乐观情绪。莱斯康制药的 GAAP 每股收益-$0.04 超出$0.03，收入 549 万美元超出$2.35 百万。</li>
<li>积极情绪：临床和公司进展：管理层表示，关键的 sotagliflozin 里程碑仍按计划进行（T1D 的 NDA 重新提交，HCM 的 SONATA 入组），而 pilavapadin 在 FDA 的第二阶段结束会议上获得积极反馈，支持第三阶段的准备——这些降低了即将到来的催化剂的风险。该公司还报告了超过 1 亿美元的额外现金来自资本筹集和诺和诺德的里程碑，增强了资产负债表。莱斯康制药报告了 2025 年第四季度财务结果并提供临床更新。</li>
<li>积极情绪：分析师升级/目标价上调：HC Wainwright 重申买入评级，并将目标价从 4 美元上调至 6 美元，暗示从当前水平有显著上行——分析师的支持可以吸引买入兴趣。Benzinga 对 HC Wainwright 目标价上调的报道。</li>
<li>中性情绪：会议材料和电话会议记录可用：该公司发布了新闻稿、幻灯片和召开了电话会议（记录可用）——对挖掘指导、现金流和试验时间表有用，但本身并不是直接的价格驱动因素。查看新闻稿/幻灯片。</li>
<li>中性情绪：多个媒体发布了财报电话会议记录和快照（Seeking Alpha, InsiderMonkey, Yahoo, WTOP）——增加了透明度和覆盖面，但主要重申了相同的业绩和更新。InsiderMonkey 财报电话会议记录。</li>
<li>消极情绪：公司仍处于亏损状态，负的股本回报率和净利润率；共识仍预计全年每股收益亏损（当前共识约为-$0.66）。持续的临床和监管风险加上负的收益预测意味着上行依赖于成功的试验和监管结果。MarketBeat 公司简介和共识预期。</li>
</ul>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的目标价</h2>
</div><p>Several research analysts have commented on LXRX shares. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Lexicon Pharmaceuticals in a research report on Thursday, January 22nd. Wall Street Zen cut shares of Lexicon Pharmaceuticals from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Saturday, November 15th. Finally, HC Wainwright upped their price objective on Lexicon Pharmaceuticals from $4.00 to $6.00 and gave the company a &#34;buy&#34; rating in a research note on Thursday. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Lexicon Pharmaceuticals currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $4.63.</p>
<div class="lb-trans"><p>几位研究分析师对 LXRX 股票发表了评论。Weiss Ratings 在 1 月 22 日的研究报告中重申了对莱斯康制药股票的 “卖出（d-）” 评级。华尔街 Zen 在 11 月 15 日的报告中将莱斯康制药的股票评级从 “买入” 下调至 “持有”。最后，HC Wainwright 在周四的研究报告中将莱斯康制药的目标价从 4.00 美元上调至 6.00 美元，并给予该公司 “买入” 评级。三位研究分析师对该股票给予了买入评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，莱斯康制药目前的共识评级为 “适度买入”，平均目标价为 4.63 美元。</p>
</div><p><strong>Get Our Latest Research Report on Lexicon Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>获取我们关于莱斯康制药的最新研究报告</strong></p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In related news, Director Raymond Debbane acquired 100,000 shares of the firm's stock in a transaction dated Monday, February 23rd. The stock was acquired at an average cost of $1.47 per share, for a total transaction of $147,000.00. Following the completion of the acquisition, the director directly owned 1,904,186 shares of the company's stock, valued at approximately $2,799,153.42. The trade was a 5.54% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Invus Global Management, Llc bought 1,538,462 shares of the company's stock in a transaction that occurred on Monday, February 2nd. The shares were purchased at an average cost of $1.30 per share, for a total transaction of $2,000,000.60. Following the acquisition, the director owned 1,538,462 shares of the company's stock, valued at $2,000,000.60. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders purchased 1,790,462 shares of company stock worth $2,369,981. 13.90% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在相关消息中，董事 Raymond Debbane 于 2 月 23 日星期一以每股平均 1.47 美元的价格收购了 100,000 股该公司的股票，总交易额为 147,000.00 美元。收购完成后，该董事直接持有公司 1,904,186 股股票，价值约为 2,799,153.42 美元。此次交易使其持股增加了 5.54%。该交易已在 SEC 的备案中披露，可通过 SEC 网站获取。此外，董事 Invus Global Management, Llc 于 2 月 2 日星期一购买了 1,538,462 股该公司的股票，购买价格为每股 1.30 美元，总交易额为 2,000,000.60 美元。收购后，该董事持有 1,538,462 股该公司的股票，价值为 2,000,000.60 美元。这代表其持股增加了∞。该购买的披露信息可在 SEC 备案中找到。在过去一个季度，内部人士购买了价值 2,369,981 美元的 1,790,462 股公司股票。目前，内部人士持有该股票的 13.90%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several hedge funds and other institutional investors have recently made changes to their positions in LXRX. UBS Group AG lifted its stake in shares of Lexicon Pharmaceuticals by 752.1% in the 4th quarter. UBS Group AG now owns 3,007,237 shares of the biopharmaceutical company's stock valued at $3,458,000 after purchasing an additional 2,654,315 shares during the last quarter. CIBC Bancorp USA Inc. bought a new stake in Lexicon Pharmaceuticals during the third quarter worth approximately $3,240,000. Millennium Management LLC grew its holdings in Lexicon Pharmaceuticals by 133.1% during the third quarter. Millennium Management LLC now owns 3,830,660 shares of the biopharmaceutical company's stock valued at $5,171,000 after purchasing an additional 2,187,396 shares during the last quarter. Marshall Wace LLP acquired a new position in Lexicon Pharmaceuticals during the fourth quarter valued at approximately $1,452,000. Finally, AQR Capital Management LLC acquired a new stake in shares of Lexicon Pharmaceuticals in the first quarter worth $541,000. 74.70% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近对 LXRX 的持仓进行了调整。瑞银集团在第四季度将其在莱克森制药的股份增加了 752.1%。瑞银集团目前拥有 3,007,237 股该生物制药公司的股票，价值 3,458,000 美元，此前在上个季度又购买了 2,654,315 股。CIBC Bancorp USA Inc. 在第三季度购买了莱克森制药的新股份，价值约 3,240,000 美元。千禧管理公司在第三季度将其在莱克森制药的持股增加了 133.1%。千禧管理公司目前拥有 3,830,660 股该生物制药公司的股票，价值 5,171,000 美元，此前在上个季度又购买了 2,187,396 股。Marshall Wace LLP 在第四季度获得了莱克森制药的新职位，价值约 1,452,000 美元。最后，AQR Capital Management LLC 在第一季度获得了莱克森制药的新股份，价值 541,000 美元。目前，74.70% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Lexicon Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>莱克森制药价格表现</h2>
</div><p>The stock has a market cap of $623.35 million, a price-to-earnings ratio of -9.03 and a beta of 0.94. The stock has a fifty day simple moving average of $1.35 and a 200-day simple moving average of $1.33. The company has a current ratio of 5.64, a quick ratio of 5.63 and a debt-to-equity ratio of 0.47.</p>
<div class="lb-trans"><p>该股票的市值为 6.2335 亿美元，市盈率为 -9.03，贝塔值为 0.94。该股票的 50 日简单移动平均为 1.35 美元，200 日简单移动平均为 1.33 美元。公司的流动比率为 5.64，速动比率为 5.63，债务与股本比率为 0.47。</p>
</div><h2>About Lexicon Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于莱克森制药</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon's approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.</p>
<div class="lb-trans"><p>莱克森制药公司是一家生物制药公司，专注于通过其专有的基因组生物学平台发现和开发新药。通过利用大规模基因敲除文库，公司识别潜在的治疗靶点，并将其推进到临床前和临床开发阶段。莱克森的做法强调将基因洞察转化为针对多种人类疾病的靶向疗法。</p>
</div><p>The company's most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.</p>
<div class="lb-trans"><p>该公司的最先进产品是乙基特洛曲司特（以品牌名 XERMELO 销售），这是一种口服治疗药物，已获批准用于管理在生长抑素类似物治疗下控制不佳的类癌综合症腹泻患者。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Lexicon Pharmaceuticals</li>
<li>BNZI stands out as a Zacks Buy. Earnings momentum and analyst upgrades align</li>
<li>J.P. Morgan is betting on this coin</li>
<li>Your name isn't on our protected list yet</li>
<li>~$1.5T SpaceX IPO: Pre-IPO Opportunity</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过莱克森制药</li>
<li>BNZI 在 Zacks 买入评级中脱颖而出。盈利势头和分析师升级一致</li>
<li>摩根大通正在押注这枚硬币</li>
<li>你的名字尚未在我们的保护名单上</li>
<li>~1.5 万亿美元的 SpaceX IPO：首次公开募股机会</li>
<li>用这四个简单步骤 “防联储” 你的银行账户</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒是通过叙述科学技术和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Lexicon Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在莱克森制药吗？</h2>
</div><p>Before you consider Lexicon Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑莱克森制药之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexicon Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而莱克森制药并不在名单上。</p>
</div><p>While Lexicon Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然莱克森制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

莱斯康制药（NASDAQ:LXRX）因收益超出预期，股价上涨 5.8%